These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 33098800)

  • 1. Effects of intensive versus standard blood pressure control on domain-specific cognitive function: a substudy of the SPRINT randomised controlled trial.
    Rapp SR; Gaussoin SA; Sachs BC; Chelune G; Supiano MA; Lerner AJ; Wadley VG; Wilson VM; Fine LJ; Whittle JC; Auchus AP; Beddhu S; Berlowitz DR; Bress AP; Johnson KC; Krousel-Wood M; Martindale-Adams J; Miller EC; Rifkin DE; Snyder JK; Tamariz L; Wolfgram DF; Cleveland ML; Yang M; Nichols LO; Bryan RN; Reboussin DM; Williamson JD; Pajewski NM;
    Lancet Neurol; 2020 Nov; 19(11):899-907. PubMed ID: 33098800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying Patients for Intensive Blood Pressure Treatment Based on Cognitive Benefit: A Secondary Analysis of the SPRINT Randomized Clinical Trial.
    Ghazi L; Shen J; Ying J; Derington CG; Cohen JB; Marcum ZA; Herrick JS; King JB; Cheung AK; Williamson JD; Pajewski NM; Bryan N; Supiano M; Sonnen J; Weintraub WS; Greene TH; Bress AP
    JAMA Netw Open; 2023 May; 6(5):e2314443. PubMed ID: 37204788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial.
    ; Williamson JD; Pajewski NM; Auchus AP; Bryan RN; Chelune G; Cheung AK; Cleveland ML; Coker LH; Crowe MG; Cushman WC; Cutler JA; Davatzikos C; Desiderio L; Erus G; Fine LJ; Gaussoin SA; Harris D; Hsieh MK; Johnson KC; Kimmel PL; Tamura MK; Launer LJ; Lerner AJ; Lewis CE; Martindale-Adams J; Moy CS; Nasrallah IM; Nichols LO; Oparil S; Ogrocki PK; Rahman M; Rapp SR; Reboussin DM; Rocco MV; Sachs BC; Sink KM; Still CH; Supiano MA; Snyder JK; Wadley VG; Walker J; Weiner DE; Whelton PK; Wilson VM; Woolard N; Wright JT; Wright CB
    JAMA; 2019 Feb; 321(6):553-561. PubMed ID: 30688979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Individualising intensive systolic blood pressure reduction in hypertension using computational trial phenomaps and machine learning: a post-hoc analysis of randomised clinical trials.
    Oikonomou EK; Spatz ES; Suchard MA; Khera R
    Lancet Digit Health; 2022 Nov; 4(11):e796-e805. PubMed ID: 36307193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kidney Disease, Hypertension Treatment, and Cerebral Perfusion and Structure.
    Kurella Tamura M; Gaussoin S; Pajewski NM; Zaharchuk G; Freedman BI; Rapp SR; Auchus AP; Haley WE; Oparil S; Kendrick J; Roumie CL; Beddhu S; Cheung AK; Williamson JD; Detre JA; Dolui S; Bryan RN; Nasrallah IM;
    Am J Kidney Dis; 2022 May; 79(5):677-687.e1. PubMed ID: 34543687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Intensive vs Standard Blood Pressure Control With Cerebral Blood Flow: Secondary Analysis of the SPRINT MIND Randomized Clinical Trial.
    Dolui S; Detre JA; Gaussoin SA; Herrick JS; Wang DJJ; Tamura MK; Cho ME; Haley WE; Launer LJ; Punzi HA; Rastogi A; Still CH; Weiner DE; Wright JT; Williamson JD; Wright CB; Bryan RN; Bress AP; Pajewski NM; Nasrallah IM
    JAMA Neurol; 2022 Apr; 79(4):380-389. PubMed ID: 35254390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Intensive vs Standard Blood Pressure Control With Magnetic Resonance Imaging Biomarkers of Alzheimer Disease: Secondary Analysis of the SPRINT MIND Randomized Trial.
    Nasrallah IM; Gaussoin SA; Pomponio R; Dolui S; Erus G; Wright CB; Launer LJ; Detre JA; Wolk DA; Davatzikos C; Williamson JD; Pajewski NM; Bryan RN;
    JAMA Neurol; 2021 May; 78(5):568-577. PubMed ID: 33683313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy.
    Launer LJ; Miller ME; Williamson JD; Lazar RM; Gerstein HC; Murray AM; Sullivan M; Horowitz KR; Ding J; Marcovina S; Lovato LC; Lovato J; Margolis KL; O'Connor P; Lipkin EW; Hirsch J; Coker L; Maldjian J; Sunshine JL; Truwit C; Davatzikos C; Bryan RN;
    Lancet Neurol; 2011 Nov; 10(11):969-77. PubMed ID: 21958949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Hypertension: SPRINT (Systolic Blood Pressure Intervention Trial).
    Soliman EZ; Ambrosius WT; Cushman WC; Zhang ZM; Bates JT; Neyra JA; Carson TY; Tamariz L; Ghazi L; Cho ME; Shapiro BP; He J; Fine LJ; Lewis CE;
    Circulation; 2017 Aug; 136(5):440-450. PubMed ID: 28512184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensive vs Standard Blood Pressure Control in Adults 80 Years or Older: A Secondary Analysis of the Systolic Blood Pressure Intervention Trial.
    Pajewski NM; Berlowitz DR; Bress AP; Callahan KE; Cheung AK; Fine LJ; Gaussoin SA; Johnson KC; King J; Kitzman DW; Kostis JB; Lerner AJ; Lewis CE; Oparil S; Rahman M; Reboussin DM; Rocco MV; Snyder JK; Still C; Supiano MA; Wadley VG; Whelton PK; Wright JT; Williamson JD
    J Am Geriatr Soc; 2020 Mar; 68(3):496-504. PubMed ID: 31840813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of Long-term Benefit of Intensive Blood Pressure Control on Residual Life Span: Secondary Analysis of the Systolic Blood Pressure Intervention Trial (SPRINT).
    Vaduganathan M; Claggett BL; Juraschek SP; Solomon SD
    JAMA Cardiol; 2020 May; 5(5):576-581. PubMed ID: 32101262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials.
    Beddhu S; Greene T; Boucher R; Cushman WC; Wei G; Stoddard G; Ix JH; Chonchol M; Kramer H; Cheung AK; Kimmel PL; Whelton PK; Chertow GM
    Lancet Diabetes Endocrinol; 2018 Jul; 6(7):555-563. PubMed ID: 29685860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Intensive Blood Pressure Control on Gait Speed and Mobility Limitation in Adults 75 Years or Older: A Randomized Clinical Trial.
    Odden MC; Peralta CA; Berlowitz DR; Johnson KC; Whittle J; Kitzman DW; Beddhu S; Nord JW; Papademetriou V; Williamson JD; Pajewski NM;
    JAMA Intern Med; 2017 Apr; 177(4):500-507. PubMed ID: 28166324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial.
    Peters R; Beckett N; Forette F; Tuomilehto J; Clarke R; Ritchie C; Waldman A; Walton I; Poulter R; Ma S; Comsa M; Burch L; Fletcher A; Bulpitt C;
    Lancet Neurol; 2008 Aug; 7(8):683-9. PubMed ID: 18614402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of Risk of Harm Associated With Intensive Blood Pressure Management Among Patients With Hypertension Who Smoke: A Secondary Analysis of the Systolic Blood Pressure Intervention Trial.
    Scarpa J; Bruzelius E; Doupe P; Le M; Faghmous J; Baum A
    JAMA Netw Open; 2019 Mar; 2(3):e190005. PubMed ID: 30848803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systolic Blood Pressure Time in Target Range and Cognitive Outcomes: Insights From the SPRINT MIND Trial.
    Li S; Jiang C; Wang Y; Lai Y; Zhao M; Li Q; Bai Y; Dai W; Guo Q; He L; Guo X; Wang W; Li S; Liu N; Jiang C; Tang R; Sang C; Long D; Du X; Dong J; Anderson CS; Ma C
    Hypertension; 2023 Aug; 80(8):1628-1636. PubMed ID: 37165869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of intensive blood pressure lowering after successful endovascular therapy in acute ischaemic stroke (BP-TARGET): a multicentre, open-label, randomised controlled trial.
    Mazighi M; Richard S; Lapergue B; Sibon I; Gory B; Berge J; Consoli A; Labreuche J; Olivot JM; Broderick J; Duhamel A; Touze E; Qureshi AI; Yavchitz A; Escalard S; Desilles JP; Redjem H; Smajda S; Fahed R; Hébert S; Maïer B; Delvoye F; Boursin P; Maacha MB; Obadia M; Sabben C; Blanc R; Savatovsky J; Piotin M;
    Lancet Neurol; 2021 Apr; 20(4):265-274. PubMed ID: 33647246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial.
    Liu J; Li Y; Ge J; Yan X; Zhang H; Zheng X; Lu J; Li X; Gao Y; Lei L; Liu J; Li J;
    Lancet; 2024 Jul; 404(10449):245-255. PubMed ID: 38945140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.
    Berlowitz DR; Foy CG; Kazis LE; Bolin LP; Conroy MB; Fitzpatrick P; Gure TR; Kimmel PL; Kirchner K; Morisky DE; Newman J; Olney C; Oparil S; Pajewski NM; Powell J; Ramsey T; Simmons DL; Snyder J; Supiano MA; Weiner DE; Whittle J;
    N Engl J Med; 2017 Aug; 377(8):733-744. PubMed ID: 28834483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trials.
    Basu S; Sussman JB; Rigdon J; Steimle L; Denton BT; Hayward RA
    PLoS Med; 2017 Oct; 14(10):e1002410. PubMed ID: 29040268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.